Thyroid cancer medullary · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cabozantinib monotherapy Variant #01 | — | R 90 983 | 28d | ~14.0 mo | ~26.6 mo | ~16 | ~R 1 455 726 PFS proxy · indirect | 3 |
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | ~10.8 mo | — | ~12 | ~R 448 066 PFS proxy · indirect | 1 |
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~8.3 mo | ~32.4 mo | ~10 | ~R 334 331 PFS proxy · indirect | 36 |
Placebo Partial | — | — | — | ~11.7 mo | ~21.1 mo | — | — | 3 |
Vandetanib monotherapy Variant #01 Partial | — | — | 28d | ~16.8 mo | — | ~19 | — | 2 |
5 of 5 regimens shown